Coherus Oncology (CHRS) EBT Margin Growth (5y) (2019 - 2026)

Coherus Oncology (CHRS) EBT Margin Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9,176.00
Dec 31, 2025 -37,331.00
Sep 30, 2025 -40,949.00
Jun 30, 2025 -48,197.00
Mar 31, 2025 -65,516.00
Dec 31, 2024 -62,937.00
Sep 30, 2024 -82,938.00
Jun 30, 2024 -56,105.00
Mar 31, 2024 -289,391.00
Jun 30, 2022 473,363.00
Mar 31, 2022 5.15 Mn
Dec 31, 2021 892,220.00
Sep 30, 2021 -9,718.00
Jun 30, 2021 42,857.00
Mar 31, 2021 31,918.00
Dec 31, 2020 52,168.00
Sep 30, 2020 101,890.00
Jun 30, 2020 90,224.00
Mar 31, 2020 66,392.00
Dec 31, 2019 44,237.00